This article has been updated with additional comments from Circulogene to clarify the company's future plans and its relationship to Atherotech, where its technology was intially developed.
NEW YORK (GenomeWeb) – Hot on the heels of several other new liquid biopsy companies, Circulogene — a new firm offering NGS detection of cancer mutations using finger stick-volume blood samples — announced recently that it has begun commercial operations out of its CLIA-certified Birmingham, Alabama lab.